

Vineet Laboratories Limited Regd.Office: SY. No. 11/A3, Saheb Nagar, Kurdu Vili, Chintal Kunta, Eshwaramma Nilayam, L B Nagar Hyderabad. CIN- L24304TG2016PLC112888 Phone: 040-24128833; Email Id: cs@vineetlabs.co.in; Website: vineetlabs.co.in

August 13, 2024

To The General Manager Department of Corporate Services BSE Limited P.J. Towers, Dalal Street, Mumbai-400 001 To The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No – C/1, G Block, Bandra Kurla Complex Bandra (East), Mumbai -400 051

Scrip Code - 543298

Scrip Code - VINEETLAB

Dear Sir/Ma'am,

Sub: Outcome of Board Meeting held on Tuesday, August 13, 2024 as required under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors of the company in its meeting held today i.e., on August 13, 2024 has considered and approved the following:

 Unaudited Standalone Financial Results of the company for the First Quarter ended on June 30, 2024 along with the Limited Review Report submitted by the Statutory Auditors.

The Board Meeting commenced at 03:00 PM and concluded at 6:00 PM.

Kindly take this information on records.

Thanking you, Best Regards,

For Vineet Laboratories Limited

Gaddam Venkata Ramana Managing Director DIN: 00031873



S No	Particulars	Quarter ended June 30,2024	Quarter ended March 31,2024	Quarter ended June 30,2023	Year ended 31 March 2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	Income from operations				
	a) Net Sales/income from operations	2,386.16	3,704.86	3,752.30	15,059.13
	Total income from operations	2,386.16	3,704.86	3,752.30	15,059.13
	Other income	37.26	41.07	2.55	46.32
1	Total Income (I + II)	2,423.42	3,745.93	3,754.85	15,105.44
1	Expenses				
	a) Cost of materials Consumed	1,673.87	3,987.09	3,030.31	13,170.41
	b) Changes in inventories of finished goods, work-in				
	progress and stock-in-trade(increase)/decrease	222.10	(1,347.08)	48.23	(1,778.50
	c) Employee benefits expenses	147.82	181.94	140.24	638.47
	d) Finance cost	113.65	172.08	95.88	478.10
	e) Depreciation and amortisation expenses	60.86	67.20	60.86	251.90
	f) Other expenses	421.88	541.36	507.55	2,308.72
	Total expenses	2,640.18	3,602.58	3,883.07	15,069.11
	Profit/(loss) before exceptional items and tax (III - IV)	(216.76)	143.35	(128.23)	36.34
T	Exceptional itmes	(210.10)	110.00	(120.20)	
'n	Profit/(loss) before Tax (V -VI)	(216.76)	143.35	(128.23)	36.34
an -	Tax expense :				
	a. Current tax (net)		12.23		(6.48
	b. Deferred tax(net)	(3.70)	(61.26)	(3.23)	(59.89
	Total tax expense	(3.70)	(49.03)	(3.23)	
x	Profit/(loss) for the period (VII-VIII)	(213.07)	192.38	(125.00)	102.71
ć	Other comprehensive income(OCI)				
	a) (i) Items that will not be reclassified to profit or loss		1.85		1.85
	(ii) Income tax relating to items that will not be				
	reclassified to profit or loss	× .	(0.47)	-	(0.47
	b) (i) Items that will be reclassified to profit or loss				
	(ii) Income tax relating to items that will be				
	reclassified to profit or loss	*	1.00		
	Total other comprehensive income/(loss)		1.38	*	1.38
	Total comprehensive income/(loss) net of tax for the				
1	Period/year (IX+X))	(213.07)	193.76	(125.00)	104.09
a	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	921.90	921.90	921.90	921.90
	Other equity				2,550.53
	Earnings per equity share (of Rs. 10/- each)				
κιν	: (not annualised for the quarters)	and the second			
	(i) Basic	(2.31)	2.09	(1.36)	1.11
	(ii) Diluted.	(2.31)	2.09	(1.36)	1.11

VINEET LABORATORIES LIMITED CIN:L24304TG2016PLC112888

Notes

1. The above statement of unaudited financial results of M/s. Vineet Laboratories Limited ("the Company"), which have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI") were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meetings held on August 13, 2024. The Statutory Auditors have carried out a limited review on the unaudited financial results pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

2.No material adjustments were made in the results for the current quarter/year which pertain to earlier periods/year. Hence, the figures have not been regrouped or reclassified.

3. The company operates in one reportable business segment i.e. Active pharmaceuticals ingredient and intermediates. Hence segmental reporting as per Ind AS 108 is not applicable.

4. The figures for the quarter ended March 31, 2024 are the balancing figures between audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the relevant financial year, which were subject to limited review.

5. These Financial Results are available on the website of BSE Limited, NSE Limited and on the company's website.

Date: August 13, 2024 Place: Hyderabad



For and on behalf of Board of Directors

Gaddam Venkata Ramana Managing Director DIN: 00031873

e

Balance sheet for the Quarter	ended 50 Juli		All amounts in Lakh
	Notes		As at
		30 June 2024	31 March 2024
ASSETS			
ion-current assets			
a) Property, plant and equipment	3	2,648.35	2,691.53
b) Financial assets			
(i) Investments	4	21.08	18.16
(ii) Other financial assets	5	141.85	141.95
c) Other non-current assets	6	19.31	16.74
		2,830.59	2,868.38
Current assets			
a) Inventories	7	4,850.76	4,939.37
b) Financial assets			
(i) Trade receivables	8	2,746.30	3,160.39
(ii) Cash and cash equivalents	9	124.27	22.78
(iii) Bank balances other than (ii) above	10	21.23	21.23
(iv) Other financial assets	5	2.70	1
c) Other current assets	6	534.90	
		8,280.16	the second se
Total assets		11,110.76	11,687.20
EQUITY AND LIABILITIES			
Equity			
(a) Equity share capital	11	921.90	921.90
(b) Other equity	12	2,337.46	2,550.53
		3,259.36	3,472.43
Liabilities			
Non-current liabilities			
(a) Financial liabilities			
(i) Borrowings	13	486.91	388.57
(b) Provisions	14	127.08	80.62
(c) Deferred tax liabilities (Net)	15	142.24	145.94
		756.24	
Current liabilities			
(a) Financial liabilities			
(i) Borrowings	13	3,747.07	4,041.39
(ii) Trade payables	16		
 total outstanding dues of micro and small enterprises; 		1,533.81	1,450.47
 total outstanding dues of creditors other than micro and small enterprises 		1,578.97	1,775.30
(iii) Other fnancial liabilities	17	26.51	40.81
(b) Other current liabilities	18	196.56	
	12.22	190.00	46.46
(c) Provisions	14		
(d) Current tax liabilities (net)	19	12.23 7,095.15	
Total equity and liabilities		11,110.76	11,687.20



For and on behalf of the Board of Directors of Vineet Laboratories Limited

la G. Venkata Ramana Managing Director DIN: 00031873

Vineet Laboratories Limited CIN:L24304TG2016PLC112888

egd Office: SY . No. 11/A3, Saheb nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana-500074, Indi. Statement of Profit and Loss for the Quarter ended 30 June, 2024

	Notes	30 June 2024	31 March 2024
Income			
Revenue from operations	20	2,386.16	15,059.13
Other income	21	37.26	46.32
Total income		2,423.42	15,105.44
Expenses	7		
Cost of material consumed	22	1,673.87	13,170.41
Changes in inventories of stock-in -trade	23	222.10	(1,778.50)
Employee benefits expense	24	147.82	638.47
Finance costs	25	113.65	478.10
Depreciation and amortisation expense	26	60.86	251.90
Other expenses	27	421.88	2,308.72
Total expenses		2,640.18	15,069.11
Profit Before Tax		(216.76)	36.34
Tax expenses	23		
Current tax expense		-	12.23
Deferred tax expense		(3.70)	(59.89)
Taxes in respect of prior periods		-	(18.71)
Total tax expenses		(3.70)	(66.37)
Profit for the year	-	(213.07)	102.71
Other Comprehensive Income ('OCI')			
(i) Items that will not be reclassified subsequently to profit or loss			
- Re-measurement gains/(losses) on defined benefit plans		-	1.85
- Income tax effect on the above		-	(0.47
(ii) Items that will be reclassified subsequently to profit or loss		-	-
Total other comprehensive income		-	1.38
Total comprehensive income for the year		(213.07)	104.09
Earnings per equity share (EPES)		1	
Basic and Diluted EPES (in absolute ₹ terms)	24	(2.31)	1.11
Nominal value per equity share (in absolute ₹ terms)		10.00	10.00

For and on behalf of the Board of Directors of Vineet Laboratories Limited



G. Venkata Ramana Managing Director DIN: 00031873



Limited Review Report on Unaudited Financial Results of M/s Vineet Laboratories Limited

Independent Auditor's Report on Quarterly and Year to Date Unaudited financial Results of M/s VINEET LABORATORIES LIMITED pursuant to regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015.

TO THE BOARD OF DIRECTORS OF Vineet Laboratories Limited

We have reviewed the accompanying unaudited financial results of **M/s Vineet Laboratories Limited**, for the quarter ended June 30, 2024. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standards on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

The procedures performed in a review are substantially less than those performed in an audit conducted in accordance with Standards on Auditing. Accordingly, we do not express an audit opinion on these financial results. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and that it contains any material misstatement.

Based on our review, nothing has come to our attention that causes us to believe that these financial statements do not give a true and fair view of the financial position of **M/s Vineet Laboratories Limited** as at June 30, 2024.

For NSVR & Associates LLP Chartered Accountants FRN: 008801S/S200060

V Gangadhara Rao N Partner M. No.219486 UDIN: 24219486BKFBBE7590

Place: Hyderabad Date: 13-08-2024.



NSVR & ASSOCIATES LLP

House No.1-89/1/42, 2nd Floor, Plot No. 41 & 43, Sri Ram Nagar Colony, Kavuri Hills, Guttala Begumpet, Madhapur, Hyderabad, Telangana - 500081. | Ph: 040 - 23391164, E-mail: info@nsvr.in